We know you enjoy data as much as we do, and thought you'd be interested in seeing ours. We answered thousands of questions and now have 50 million+ studies in our bank!
Here were the most popular topics in 2023:
1. What is the risk of serotonin syndrome with linezolid and other serotonergic drugs?
While there have been reports of serotonin syndrome in patients taking linezolid with other serotonergic drugs, the reported incidence appears to be low. Retrospective studies h... Read More →
#Linezolid #Serotonin syndrome
2. What data is available for tenecteplase versus alteplase for STEMI and pulmonary embolism?
For the treatment of ST-elevation myocardial infarction (STEMI), there appears to be a lack of considerable differences in efficacy between tenecteplase and alteplase. However, ... Read More →
#Tenecteplase #Alteplase #Tpa #Pulmonary embolism
3. What is the most effective Vaccine for RSV?
Given the recent FDA approval for both respiratory syncytial virus (RSV) vaccines, Arexvy or AbrysvoTM, the CDC recommends the administration of either vaccine, to prevent sympt... Read More →
#Rsv #Abrysvo #Arexvy
4. What are the differences between Arexvy versus Abrysvo? Are there advantages or disadvantages between the two RSV vaccines?
Given the recent FDA approval for both respiratory syncytial virus (RSV) vaccines, Arexvy or Abrysvo™, the CDC recommends the administration of either vaccine, to prevent sympto... Read More →
#Arexvy #Abrysvo #Rsv
5. Are there any data that support decreasing duration of DOAC loading doses for DVT/PE treatment after initial enoxaparin use?
Recent clinical guidelines have not addressed if DOAC loading doses can be omitted or shortened following initial treatment with heparin or enoxaparin for VTE treatment. Data ev... Read More →
#Doac #Loading dose #Apixaban #Rivaroxaban
6. What is the best DOAC for underweight individuals (i.e., 30 kg patients) for treatment of PE?
Given the paucity of clinical data evaluating the use of DOACs in underweight patients, a definitive conclusion on the preferred DOAC for the treatment of PE cannot be made. Ide... Read More →
#Doac #Direct oral anticoagulants #Underweight #Pulmonary embolism #Apixaban #Rivaroxaban
Share
the U.S. Food and Drug Administration (FDA) has approved AQNEURSA™ (levacetylleucine) for the treatment of neurological manifes...
The U.S. Food and Drug Administration recently approved Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a f...
Transforming Type 2 Diabetes Treatment: Key Findings from the QWINT-2 (once-weekly insulin therapy) Trial Written by Tanmaya P...
